44 results on '"Madsen LW"'
Search Results
2. The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.
- Author
-
Nyborg NC, Mølck AM, Madsen LW, Bjerre Knudsen L, Nyborg, Niels C B, Mølck, Anne-Marie, Madsen, Lars W, and Knudsen, Lotte Bjerre
- Abstract
Glucagon-like peptide (GLP)-1 analogs have been implicated as a risk factor for pancreatitis in humans. We investigated whether liraglutide, the once-daily human GLP-1 analog, induces pancreatitis in rats, mice, and monkeys. Pancreata from mice, rats, and nonhuman primates were examined macro- and microscopically. Evaluation of preneoplastic proliferative lesions in the pancreata from nonhuman primates was performed. After 2 years of treatment, 3 of 79 male mice in the control group and 2, 1, 1, and 1 mice in the different liraglutide groups (of 67-79 mice per group) had pancreatitis based on microscopic criteria. For females, the numbers were 0 of 79 mice in the control group and 3 mice in all the liraglutide groups (of 66-76 mice per group). Pancreatitis was not the cause of death in any animals. There were no cases of pancreatitis, macroscopically or microscopically, in 400 rats. Neither pancreatitis nor preneoplastic proliferative lesions was found in monkeys dosed for 87 weeks, with plasma liraglutide exposure 60-fold higher than that observed in humans at the maximal clinical dose. In conclusion, liraglutide did not induce pancreatitis in mice, rats, or monkeys when dosed for up to 2 years and at exposure levels up to 60 times higher than in humans. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
3. Effect of direct-acting antivirals on the titers of human pegivirus 1 during treatment of chronic hepatitis C patients.
- Author
-
Fahnøe U, Madsen LW, Christensen PB, Sølund CS, Mollerup S, Pinholt M, Weis N, Øvrehus A, and Bukh J
- Subjects
- Humans, Male, Female, Genotype, Quinoxalines therapeutic use, Middle Aged, Pyrrolidines, Sulfonamides therapeutic use, RNA, Viral blood, RNA, Viral genetics, Hepacivirus genetics, Hepacivirus drug effects, Genome, Viral, Adult, Aged, Viral Load drug effects, Metagenomics, Cyclopropanes, Aminoisobutyric Acids, Phylogeny, Drug Combinations, Antiviral Agents therapeutic use, Hepatitis C, Chronic drug therapy, Hepatitis C, Chronic virology, Benzimidazoles therapeutic use, Sofosbuvir therapeutic use, Pegivirus drug effects, Coinfection drug therapy, Coinfection virology, Flaviviridae Infections drug therapy, Flaviviridae Infections virology
- Abstract
Coinfections with human pegivirus 1 (HPgV-1) are common in chronic hepatitis C virus (HCV) patients. However, little is known about whether HPgV-1 is affected by direct-acting antivirals during HCV treatment. Metagenomic analysis and reverse transcriptase-quantitative PCR (RT-qPCR) were performed on RNA from the plasma of 88 selected chronic HCV patients undergoing medical treatment. Twenty (23%) of these HCV patients had HPgV-1 coinfections and were followed by RT-qPCR during treatment and follow-up to investigate HPgV-1 RNA titers. Recovered sequences could be assembled to complete HPgV-1 genomes, and most formed a genotype 2 subclade. All HPgV-1 viral genomic regions were under negative purifying selection. Glecaprevir/pibrentasvir treatment in five patients did not consistently lower the genome titers of HPgV-1. In contrast, a one log
10 drop of HPgV-1 titers at week 2 was observed in 10 patients during treatment with sofosbuvir-containing regimens, sustained to the end of treatment (EOT) and in two cases decreasing to below the detection limit of the assay. For the five patients treated with ledipasvir/sofosbuvir with the inclusion of pegylated interferon, titers decreased to below the detection limit at week 2 and remained undetectable to EOT. Subsequently, the HPgV-1 titer rebounded to pretreatment levels for all patients. In conclusion, we found that HCV treatment regimens that included the polymerase inhibitor sofosbuvir resulted in decreases in HPgV-1 titers, and the addition of pegylated interferon increased the effect on patients with coinfections. This points to the high specificity of protease and NS5A inhibitors toward HCV and the more broad-spectrum activity of sofosbuvir and especially pegylated interferon., Importance: Human pegivirus 1 coinfections are common in hepatitis C virus (HCV) patients, persisting for years. However, little is known about how pegivirus coinfections are affected by treatment with pangenotypic direct-acting antivirals (DAAs) against HCV. We identified human pegivirus by metagenomic analysis of chronic HCV patients undergoing protease, NS5A, and polymerase inhibitor treatment, in some patients with the addition of pegylated interferon, and followed viral kinetics of both viruses to investigate treatment effects. Only during HCV DAA treatment regimens that included the more broad-spectrum drug sofosbuvir could we detect a consistent decline in pegivirus titers that, however, rebounded to pretreatment levels after treatment cessation. The addition of pegylated interferon gave the highest effect with pegivirus titers decreasing to below the assay detection limit, but without clearance. These results reveal the limited effect of frontline HCV drugs on the closest related human virus, but sofosbuvir appeared to have the potential to be repurposed for other viral diseases.- Published
- 2024
- Full Text
- View/download PDF
4. Sotrovimab lost neutralization efficacy against SARS-CoV-2 subvariants but remained clinically effective: Were monoclonal antibodies against COVID-19 rejected too early?
- Author
-
Bang LL, Madsen LW, Pedersen RM, Nilsson AC, Johansen IS, and Andersen TE
- Subjects
- Humans, COVID-19 Drug Treatment, SARS-CoV-2 immunology, COVID-19 immunology, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Neutralizing blood, Antibodies, Neutralizing therapeutic use, Antibodies, Viral blood, Antibodies, Monoclonal therapeutic use
- Abstract
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
- Published
- 2024
- Full Text
- View/download PDF
5. Development of antibody levels and subsequent decline in individuals with vaccine induced and hybrid immunity to SARS-CoV-2.
- Author
-
Reekie J, Stovring H, Nielsen H, Johansen IS, Benfield T, Wiese L, Stærke NB, Iversen K, Mustafa AB, Petersen KT, Juhl MR, Knudsen LS, Iversen MB, Andersen SD, Larsen FD, Baerends EAM, Lindvig SO, Rasmussen LD, Madsen LW, Bannister W, Jensen TO, Dietz LL, Ostrowski SR, Østergaard L, Tolstrup M, Lundgren JD, and Søgaard OS
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Denmark, Aged, Vaccination, Young Adult, Antibodies, Viral blood, SARS-CoV-2 immunology, COVID-19 immunology, COVID-19 prevention & control, Immunoglobulin G blood, Immunoglobulin G immunology, COVID-19 Vaccines immunology, COVID-19 Vaccines administration & dosage, BNT162 Vaccine immunology, BNT162 Vaccine administration & dosage, Spike Glycoprotein, Coronavirus immunology
- Abstract
Objectives: This study aimed to compare antibody trajectories among individuals with SARS-CoV-2 hybrid and vaccine-induced immunity., Methods: Danish adults receiving three doses of BTN162b2 or mRNA-1237 were included prior to first vaccination (Day 0). SARS-CoV-2 anti-spike IgG levels were assessed before each vaccine dose, at Day 90, Day 180, 28 days after 3rd vaccination (Day 251), Day 365, and prior to 4th vaccination (Day 535). SARS-CoV-2 PCR results were extracted from the national microbiology database. Mixed-effect multivariable linear regression investigated the impact of hybrid-immunity (stratified into 4 groups: no hybrid immunity, PCR+ prior to 3rd dose, PCR+ after 3rd dose and before Day 365, PCR+ after Day 365) on anti-spike IgG trajectories., Results: A total of 4,936 individuals were included, 47% developed hybrid-immunity. Anti-spike IgG increases were observed in all groups at Day 251, with the highest levels in those PCR+ prior to 3rd dose (Geometric Mean; 535,647AU/mL vs. 374,665AU/mL with no hybrid-immunity, P<0.0001). Further increases were observed in participants who developed hybrid immunity after their 3rd dose. Anti-spike IgG levels declined from Day 251-535 in individuals without hybrid-immunity and in those who developed hybrid-immunity prior to their 3rd dose, with lower rate of decline in those with hybrid-immunity., Conclusion: Hybrid-immunity results in higher and more durable antibody trajectories in vaccinated individuals., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
6. Culturing of SARS-CoV-2 from patient samples: Protocol for optimal virus recovery and assessment of infectious viral load.
- Author
-
Bang LL, Tornby DR, Pham STD, Assing K, Möller S, Palarasah Y, Madsen LW, Thomsen KG, Johansen IS, Pedersen RM, and Andersen TE
- Subjects
- Humans, Viral Load, COVID-19 Testing, Specimen Handling methods, RNA, Viral, SARS-CoV-2, COVID-19 diagnosis
- Abstract
Optimal sampling, preservation, and culturing of SARS-CoV-2 from COVID-19 patients are critical for successful recovery of virus isolates and to accurately estimate contagiousness of the patient. In this study, we investigated the influence of the type of sampling media, storage time, freezing conditions, sterile filtration, and combinations of these to determine the optimal pre-analytic conditions for virus recovery and estimation of infectious viral load in COVID-19 patients. Further, we investigated the viral shedding kinetics and mucosal antibody response in 38 COVID-19 hospitalized patients. We found Universal Transport Medium (Copan) to be the most optimal medium for preservation of SARS-CoV-2 infectivity. Our data showed that the probability of a positive viral culture was strongly correlated to Ct values, however some samples did not follow the general trend. We found a significant correlation between plaque forming units and levels of mucosal antibodies and found that high levels of mucosal antibodies correlated with reduced chance of isolating the virus. Our data reveals essential parameters to consider from specimen collection over storage to culturing technique for optimal chance of isolating SARS-CoV-2 and accurately estimating patient contagiousness., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
7. Combining cross-sectional survey and register data improved the estimate of hepatitis C prevalence among patients attending a psychiatric emergency department in Denmark.
- Author
-
Rose TV, Christensen PB, Hjorth P, Madsen LW, Hansen JF, Dröse S, Harvald GB, Røge BT, and Øvrehus ALH
- Subjects
- Humans, Cross-Sectional Studies, Prevalence, Hepacivirus, Emergency Service, Hospital, Hepatitis C Antibodies, Denmark epidemiology, Hepatitis C diagnosis, Hepatitis C epidemiology
- Abstract
Background: The prevalence of hepatitis C (HCV) among psychiatric patients is elevated compared to the background population in many studies, but the prevalence among Danish psychiatric patients is unknown. The aim of the study was to determine the HCV prevalence and the proportion of the psychiatric patient population that remains to be diagnosed and treated in a Danish setting., Methods: During a 5-month period, patients attending the psychiatric emergency room in Vejle, Denmark, were offered point-of-care anti-HCV testing. Previous hepatitis C tests for all patients attending the Psychiatric Department in the study period were extracted from the national laboratory database (DANVIR). We combined the survey and register data in a capture-recapture estimate of undiagnosed patients with HCV., Results: During the study 24.9% (589 of 2364) patients seen at the psychiatric department attended the emergency room. The prevalence of anti-HCV among those tested in the emergency room was 1.6%. The laboratory register identified 595/2364 patients previously tested for anti-HCV with a positive prevalence of 6.1%. The undiagnosed anti-HCV positives among the 1483 never tested was estimated to 1.1%. Thus the total estimated prevalence of anti-HCV was 2.3% (54/2364, 95% CI 1.7%-3.0%) in the population, of whom 70.4% had been diagnosed, and 72.2% of diagnosed patients had received treatment or cleared HCV., Conclusion: Combining survey and register data showed that the WHO target of 90% diagnosed and 80% treated was not met. To eliminate HCV in the psychiatric population, both undiagnosed and untreated patients must be targeted.
- Published
- 2024
- Full Text
- View/download PDF
8. Full-length sequence analysis of hepatitis C virus genotype 3b strains and development of an in vivo infectious 3b cDNA clone.
- Author
-
Bajpai PS, Collignon L, Sølund C, Madsen LW, Christensen PB, Øvrehus A, Weis N, Holmbeck K, Fahnøe U, and Bukh J
- Subjects
- Animals, Humans, Mice, Antiviral Agents therapeutic use, DNA, Complementary genetics, Genotype, Sequence Analysis, Hepacivirus genetics, Hepatitis C virology, Genome, Viral
- Abstract
Importance: HCV genotype 3b is a difficult-to-treat subtype, associated with accelerated progression of liver disease and resistance to antivirals. Moreover, its prevalence has significantly increased among persons who inject drugs posing a serious risk of transmission in the general population. Thus, more genetic information and antiviral testing systems are required to develop novel therapeutic options for this genotype 3 subtype. We determined the complete genomic sequence and complexity of three genotype 3b isolates, which will be beneficial to study its biology and evolution. Furthermore, we developed a full-length in vivo infectious cDNA clone of genotype 3b and showed its robustness and genetic stability in human-liver chimeric mice. This is, to our knowledge the first reported infectious cDNA clone of HCV genotype 3b and will provide a valuable tool to evaluate antivirals and neutralizing antibodies in vivo , as well as in the development of infectious cell culture systems required for further research., Competing Interests: N.W. has been Clinical Investigator for Abbvie and MSD without relation to the present work. The remaining authors declare no conflicts of interest.
- Published
- 2023
- Full Text
- View/download PDF
9. Omicron Variant-Specific Serological Imprinting Following BA.1 or BA.4/5 Bivalent Vaccination and Previous SARS-CoV-2 Infection: A Cohort Study.
- Author
-
Baerends EAM, Reekie J, Andreasen SR, Stærke NB, Raben D, Nielsen H, Petersen KT, Johansen IS, Lindvig SO, Madsen LW, Wiese L, Iversen MB, Benfield T, Iversen KK, Larsen FD, Andersen SD, Juhl AK, Dietz LL, Hvidt AK, Ostrowski SR, Krause TG, Østergaard L, Søgaard OS, Lundgren J, and Tolstrup M
- Subjects
- Humans, SARS-CoV-2 genetics, Cohort Studies, Prospective Studies, Vaccination, COVID-19 Vaccines, Vaccines, Combined, Antibodies, Viral, Antibodies, Neutralizing, COVID-19 prevention & control
- Abstract
Background: Continuous evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outpaces monovalent vaccine cross-protection to new viral variants. Consequently, bivalent coronavirus disease 2019 (COVID-19) vaccines including Omicron antigens were developed. The contrasting immunogenicity of the bivalent vaccines and the impact of prior antigenic exposure on new immune imprinting remains to be clarified., Methods: In the large prospective ENFORCE cohort, we quantified spike-specific antibodies to 5 Omicron variants (BA.1 to BA.5) before and after BA.1 or BA.4/5 bivalent booster vaccination to compare Omicron variant-specific antibody inductions. We evaluated the impact of previous infection and characterized the dominant antibody responses., Results: Prior to the bivalent fourth vaccine, all participants (N = 1697) had high levels of Omicron-specific antibodies. Antibody levels were significantly higher in individuals with a previous polymerase chain reaction positive (PCR+) infection, particularly for BA.2-specific antibodies (geometric mean ratio [GMR] 6.79, 95% confidence interval [CI] 6.05-7.62). Antibody levels were further significantly boosted in all individuals by receiving either of the bivalent vaccines, but greater fold inductions to all Omicron variants were observed in individuals with no prior infection. The BA.1 bivalent vaccine generated a dominant response toward BA.1 (adjusted GMR 1.31, 95% CI 1.09-1.57) and BA.3 (1.32, 1.09-1.59) antigens in individuals with no prior infection, whereas the BA.4/5 bivalent vaccine generated a dominant response toward BA.2 (0.87, 0.76-0.98), BA.4 (0.85, 0.75-0.97), and BA.5 (0.87, 0.76-0.99) antigens in individuals with a prior infection., Conclusions: Vaccination and previous infection leave a clear serological imprint that is focused on the variant-specific antigen. Importantly, both bivalent vaccines induce high levels of Omicron variant-specific antibodies, suggesting broad cross-protection of Omicron variants., Competing Interests: Potential conflicts of interest. N. B. S. declares to have served as an investigator in clinical trials sponsored by Pfizer, Gilead, and Bavarian Nordic, and AstraZeneca. H. N. declares to have been on advisory boards for GSK and MSD and reports grants or contracts from Novo Nordisk Foundation (payment to institution, RCT of brain abscess treatment strategy). T. B. declares receipt of unrestricted grants from Novo Nordisk Foundation, Simonsen Foundation, Lundbeck Foundation, Kai Foundation, Erik and Susanna Olesen's Charitable Fund, GSK, Pfizer, Gilead Sciences, and MSD; and being advisory board member for GSK, Pfizer, Gilead Sciences, MSD, Janssen, and Astra Zeneca; and being principal investigator on clinical trials conducted by Pfizer, Boehringer Ingelheim, Gilead Sciences, MSD, Roche, Novartis, Kancera AB, Bavarian Nordic, and Janssen; and being board member on Pentabase; and receiving consulting fees from GSK and Pfizer; and receiving honorarium for lectures from GSK, Pfizer, Gilead Sciences, Boehringer Ingelheim, Abbvie, Astra Zeneca, and Bavarian Nordic; and receiving donation of trial medication (baricitinib) from Eli Lilly. M. T. declares to be on a Data Safety Monitoring Board for ImmunoCore. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
- Published
- 2023
- Full Text
- View/download PDF
10. Humoral antibody response following mRNA vaccines against SARS-CoV-2 in solid organ transplant recipients; a status after a fifth and bivalent vaccine dose.
- Author
-
Christophorou E, Nilsson AC, Petersen I, Lindvig SO, Davidsen JR, Abazi R, Poulsen MK, Pedersen RM, Justesen US, Johansen NE, Bistrup C, Madsen LW, and Johansen IS
- Subjects
- Humans, Antibody Formation, BNT162 Vaccine, Breakthrough Infections, Immunoglobulin G, mRNA Vaccines, Prospective Studies, SARS-CoV-2, Vaccines, Combined, COVID-19 prevention & control, COVID-19 Vaccines adverse effects, Organ Transplantation adverse effects
- Abstract
Background: In solid organ transplant (SOT) recipients, the humoral response following COVID-19 vaccination is reduced, as a result of their immunosuppressed treatment. In this study, we investigated antibody concentrations after booster vaccinations until the fifth dose, the latter by monovalent or bivalent BA1 or BA4/5 vaccines. In addition, we evaluated the efficacy of vaccination by recording breakthrough infections, hospitalizations, and deaths., Method: This prospective cohort study included 438 SOT recipients (>18 years) vaccinated with mRNA vaccines against COVID-19 from January 2021 until March 2023. Blood samples were drawn before and after each vaccination and tested for SARS-CoV-2 spike RBD IgG antibodies with the lowest and highest cut-off at 7.1 and 5,680 BAU/mL, respectively. Vaccine information, breakthrough infections, and hospitalizations were collected from the medical records., Results: Most participants received BNT162b2 and 61.4% received five vaccine doses. The response proportion in SOT recipients increased from 86.7% after the fourth dose to 93.0% following the fifth dose. Antibody concentration decreased with 142.7 BAU/mL between the third and fourth dose (median 132 days, Quartile 1: 123, Quartile 3: 148) and 234.3 BAU/mL between the fourth and fifth (median 250 days, Quartile 1: 241, Quartile 3: 262) dose among those without breakthrough infection (p=0.34). When comparing the Omicron BA.1 or Omicron BA.4/BA.5 adapted vaccines, no significant differences in antibody concentration were found, but 20.0% of SOT recipients receiving a monovalent fifth vaccine dose had a breakthrough infection compared to 4.0% and 7.9% among those who received BA.1 and BA.4/BA.5 adapted vaccines, respectively (p=0.04). Since January 2021, 240 (54.8%) participants had a breakthrough infection, and 22 were hospitalized, but no deaths were observed., Conclusions: The fifth COVID-19 vaccine dose raised antibody response to 93.0% of the study population. Additional booster doses, as well as bivalent vaccines, led to higher levels of antibody concentration in SOT recipients. We found a lower incidence of breakthrough infections among SOT recipients after receiving a bivalent vaccine as a fifth dose compared to those receiving a monovalent dose. Antibody concentrations did not wane when the time between doses was prolonged from four to eight months., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Christophorou, Nilsson, Petersen, Lindvig, Davidsen, Abazi, Poulsen, Pedersen, Justesen, Johansen, Bistrup, Madsen and Johansen.)
- Published
- 2023
- Full Text
- View/download PDF
11. SARS-CoV-2 vaccine-induced antibodies protect against Omicron breakthrough infection.
- Author
-
Baerends EAM, Hvidt AK, Reekie J, Søgaard OS, Stærke NB, Raben D, Nielsen H, Petersen KT, Juhl MR, Johansen IS, Lindvig SO, Madsen LW, Wiese L, Knudsen LS, Iversen MB, Benfield T, Iversen KK, Andersen SD, Juhl AK, Dietz LL, Andreasen SR, Fischer TK, Erikstrup C, Valentiner-Branth P, Lundgren J, Østergaard L, and Tolstrup M
- Abstract
SARS-CoV-2 Omicron quickly spread globally, also in regions with high vaccination coverage, emphasizing the importance of exploring the immunological requirements for protection against Omicron breakthrough infection. The test-negative matched case-control study (N = 964) characterized Omicron breakthrough infections in triple-vaccinated individuals from the ENFORCE cohort. Within 60 days before a PCR test spike-specific IgG levels were significantly lower in cases compared to controls (GMR [95% CI] for BA.2: 0.83 [0.73-0.95], p = 0.006). Multivariable logistic regression showed significant associations between high antibody levels and lower odds of infection (aOR [95% CI] for BA.2 spike-specific IgG: 0.65 [0.48-0.88], p = 0.006 and BA.2 ACE2-blocking antibodies: 0.46 [0.30-0.69], p = 0.0002). A sex-stratified analysis showed more pronounced associations for females than males. High levels of vaccine-induced antibodies provide partial protection against Omicron breakthrough infections. This is important knowledge to further characterize a threshold for protection against new variants and to estimate the necessity and timing of booster vaccination., Competing Interests: N.B.S. declares to have served as an investigator in clinical trials sponsored by Pfizer, Gilead, and Bavarian Nordic. H.N. declares to have been on advisory boards for GSK and MSD. T.B. declares receipt of unrestricted grants from Novo Nordisk Foundation, Simonsen Foundation, Lundbeck Foundation, Kai Foundation, Erik and Susanna Olesen’s Charitable Fund, GSK, Pfizer, Gilead Sciences, and MSD; and being advisory board member for GSK, Pfizer, Gilead Sciences, MSD, Janssen, and Astra Zeneca; and being principal investigator on clinical trials conducted by Pfizer, Boehringer Ingelheim, Gilead Sciences, MSD, Roche, Novartis, Kancera AB, Bavarian Nordic, and Janssen; and being board member on Pentabase; and receiving consulting fees from GSK and Pfizer; and receiving honorarium for lectures from GSK, Pfizer, Gilead Sciences, Boehringer Ingelheim, AbbVie, Astra Zeneca, and Bavarian Nordic; and receiving donation of trial medication (baricitinib) from Eli Lilly. MT declares to be on a Data Safety Monitoring Board for Immunocore. The remaining authors declare no competing interests., (© 2023 The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
12. Viral dynamics of SARS-CoV-2 in immunocompromised patients.
- Author
-
Utzon AN, Johansen IS, Bang LL, Pedersen RM, Andersen TE, and Madsen LW
- Subjects
- Humans, SARS-CoV-2 genetics, Antibodies, Monoclonal, Immunocompromised Host, Antiviral Agents therapeutic use, COVID-19
- Abstract
Objectives: Immunocompromised patients infected with SARS-CoV-2 have been shown to shed replicable virus for a prolonged period of time, and the duration of isolation can therefore be difficult to estimate. The objective of this study was to evaluate the viral load dynamic in non-hospitalized immunocompromised patients infected with SARS-CoV-2 and treated with monoclonal antibodies (mAbs) or antivirals., Methods: Oropharyngeal swabs for RT-PCR and viral culture were collected from 29 immunocompromised patients before treatment with mAbs or antivirals and at days 5 and 15 after treatment. Overall, 12 patients were infected with the subvariant Omicron BA.1, 12 with Omicron BA.2, two with the Delta variant and for three patients determination of the variant were inconclusive., Results: Before treatment with mAbs or antivirals, 22 of 29 patients (76% [95% CI, 56-90]) shed replicative SARS-CoV-2. At day 5, 21 patients (72% [95% CI, 53-87]) still tested RT-PCR-positive, but for 14 patients (48% [95% CI, 29-67]) there were no replicative virus in culture. At day 15, 16 patients (55% [95% CI, 36-74%]) tested positive but only two patients (7% [95%CI, 1-23]) had replicative virus., Discussion: Half of the patients in this cohort had no viable virus after 5 days and only two patients had replicative virus after 15 days. This could indicate that the current CDC recommendations of an isolation period of 20 days for immunocompromised patients infected with SARS-CoV-2 could be reduced, but larger studies are needed to estimate the isolation duration for immunocompromised patients., (Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
13. Serum Neutralization of Omicron XBB.1.5 in Kidney Transplant Recipients After Bivalent mRNA Booster Vaccination.
- Author
-
Pedersen RM, Bang LL, Holm DK, Madsen LW, Johansen IS, Jensen TG, Justesen US, Bistrup C, and Andersen TE
- Published
- 2023
- Full Text
- View/download PDF
14. Impact of age and comorbidities on SARS-CoV-2 vaccine-induced T cell immunity.
- Author
-
Dietz LL, Juhl AK, Søgaard OS, Reekie J, Nielsen H, Johansen IS, Benfield T, Wiese L, Stærke NB, Jensen TØ, Jakobsen SF, Olesen R, Iversen K, Fogh K, Bodilsen J, Petersen KT, Larsen L, Madsen LW, Lindvig SO, Holden IK, Raben D, Andersen SD, Hvidt AK, Andreasen SR, Baerends EAM, Lundgren J, Østergaard L, and Tolstrup M
- Abstract
Background: Older age and chronic disease are important risk factors for developing severe COVID-19. At population level, vaccine-induced immunity substantially reduces the risk of severe COVID-19 disease and hospitalization. However, the relative impact of humoral and cellular immunity on protection from breakthrough infection and severe disease is not fully understood., Methods: In a study cohort of 655 primarily older study participants (median of 63 years (IQR: 51-72)), we determined serum levels of Spike IgG antibodies using a Multiantigen Serological Assay and quantified the frequency of SARS-CoV-2 Spike-specific CD4 + and CD8 + T cells using activation induced marker assay. This enabled characterization of suboptimal vaccine-induced cellular immunity. The risk factors of being a cellular hypo responder were assessed using logistic regression. Further follow-up of study participants allowed for an evaluation of the impact of T cell immunity on breakthrough infections., Results: We show reduced serological immunity and frequency of CD4 + Spike-specific T cells in the oldest age group (≥75 years) and higher Charlson Comorbidity Index (CCI) categories. Male sex, age group ≥75 years, and CCI > 0 is associated with an increased likelihood of being a cellular hypo-responder while vaccine type is a significant risk factor. Assessing breakthrough infections, no protective effect of T cell immunity is identified., Conclusions: SARS-CoV-2 Spike-specific immune responses in both the cellular and serological compartment of the adaptive immune system increase with each vaccine dose and are progressively lower with older age and higher prevalence of comorbidities. The findings contribute to the understanding of the vaccine response in individuals with increased risk of severe COVID-19 disease and hospitalization., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
15. Serum Neutralization of Omicron BA.5, BA.2 and BA.1 in Triple Vaccinated Kidney Transplant Recipients.
- Author
-
Pedersen RM, Bang LL, Tornby DS, Nilsson AC, Nielsen C, Madsen LW, Johansen IS, Sydenham TV, Jensen TG, Justesen US, Vitved L, Palarasah Y, Bistrup C, and Andersen TE
- Published
- 2023
- Full Text
- View/download PDF
16. Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections.
- Author
-
Pedersen RM, Bang LL, Tornby DS, Madsen LW, Holm DK, Sydenham TV, Johansen IS, Jensen TG, Justesen US, and Andersen TE
- Subjects
- Humans, BNT162 Vaccine, SARS-CoV-2, Vaccination, Antibodies, Viral, Antibodies, Neutralizing, COVID-19 prevention & control, Viral Vaccines
- Abstract
Worldwide, millions of persons have received multiple COVID-19 vaccinations and subsequently recovered from SARS-CoV-2 Omicron breakthrough infections. In 2 small, matched cohorts (n = 12, n = 24) in Denmark, we found Omicron BA.1/BA.2 breakthrough infection after 3-dose BNT162b2 vaccination provided improved Omicron BA.5 neutralization over 3-dose vaccination alone.
- Published
- 2022
- Full Text
- View/download PDF
17. Characteristics associated with serological COVID-19 vaccine response and durability in an older population with significant comorbidity: the Danish Nationwide ENFORCE Study.
- Author
-
Søgaard OS, Reekie J, Johansen IS, Nielsen H, Benfield T, Wiese L, Stærke NB, Iversen K, Fogh K, Bodilsen J, Iversen M, Knudsen LS, Klastrup V, Larsen FD, Andersen SD, Hvidt AK, Andreasen SR, Madsen LW, Lindvig SO, Øvrehus A, Ostrowski SR, Abildgaard C, Matthews C, Jensen TO, Raben D, Erikstrup C, Fischer TK, Tolstrup M, Østergaard L, and Lundgren J
- Subjects
- Aged, Angiotensin-Converting Enzyme 2, Antibodies, Blocking, Comorbidity, Denmark epidemiology, Female, Humans, Immunoglobulin G, Male, Middle Aged, SARS-CoV-2, Spike Glycoprotein, Coronavirus immunology, Vaccination, mRNA Vaccines, Antibodies, Viral blood, COVID-19 epidemiology, COVID-19 prevention & control, COVID-19 Vaccines immunology
- Abstract
Objectives: To identify individual characteristics associated with serological COVID-19 vaccine responsiveness and the durability of vaccine-induced antibodies., Methods: Adults without history of SARS-CoV-2 infection from the Danish population scheduled for SARS-CoV-2 vaccination were enrolled in this parallel group, phase 4 study. SARS-CoV-2 Spike IgG and Spike-ACE2-receptor-blocking antibodies were measured at days 0, 21, 90, and 180. Vaccine responsiveness was categorized according to Spike IgG and Spike-ACE2-receptor-blocking levels at day 90 after first vaccination. Nondurable vaccine response was defined as day-90 responders who no longer had significant responses by day 180., Results: Of 6544 participants completing two vaccine doses (median age 64 years; interquartile range: 54-75), 3654 (55.8%) received BTN162b2, 2472 (37.8%) mRNA-1273, and 418 (6.4%) ChAdOx1 followed by an mRNA vaccine. Levels of both types of antibodies increased from baseline to day 90 and then decreased to day 180. The decrease was more pronounced for levels of Spike-ACE2-receptor-blocking antibodies than for Spike IgG. Proportions with vaccine hyporesponsiveness and lack of durable response were 5.0% and 12.1% for Spike IgG and 12.7% and 39.6% for Spike-ACE2-receptor-blocking antibody levels, respectively. Male sex, vaccine type, and number of comorbidities were associated with all four outcomes. Additionally, age ≥75 years was associated with hyporesponsiveness for Spike-ACE2-receptor-blocking antibodies (adjusted odds ratio: 1.59; 95% confidence interval: 1.25-2.01) but not for Spike IgG., Discussion: Comorbidity, male sex, and vaccine type were risk factors for hyporesponsiveness and nondurable response to COVID-19 vaccination. The functional activity of vaccine-induced antibodies declined with increasing age and had waned to pre-second-vaccination levels for most individuals after 6 months., (Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
18. Levels of SARS-CoV-2 antibodies among fully vaccinated individuals with Delta or Omicron variant breakthrough infections.
- Author
-
Stærke NB, Reekie J, Nielsen H, Benfield T, Wiese L, Knudsen LS, Iversen MB, Iversen K, Fogh K, Bodilsen J, Juhl MR, Lindvig SO, Øvrehus A, Madsen LW, Klastrup V, Andersen SD, Juhl AK, Andreasen SR, Ostrowski SR, Erikstrup C, Fischer TK, Tolstrup M, Østergaard L, Johansen IS, Lundgren J, and Søgaard OS
- Subjects
- Antibodies, Viral, COVID-19 Vaccines, Humans, Immunoglobulin G, COVID-19, SARS-CoV-2
- Abstract
SARS-CoV-2 variants of concern have continuously evolved and may erode vaccine induced immunity. In this observational cohort study, we determine the risk of breakthrough infection in a fully vaccinated cohort. SARS-CoV-2 anti-spike IgG levels were measured before first SARS-CoV-2 vaccination and at day 21-28, 90 and 180, as well as after booster vaccination. Breakthrough infections were captured through the Danish National Microbiology database. incidence rate ratio (IRR) for breakthrough infection at time-updated anti-spike IgG levels was determined using Poisson regression. Among 6076 participants, 127 and 364 breakthrough infections due to Delta and Omicron variants were observed. IRR was 0.29 (95% CI 0.15-0.56) for breakthrough infection with the Delta variant, comparing the highest and lowest quintiles of anti-spike IgG. For Omicron, no significant differences in IRR were observed. These results suggest that quantitative level of anti-spike IgG have limited impact on the risk of breakthrough infection with Omicron., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
19. Immunological Characteristics of Patients Receiving Ultra-Short Treatment for Chronic Hepatitis C.
- Author
-
Madsen LW, Christensen PB, Øvrehus A, Bryde DMS, Holm DK, Lillevang ST, and Nielsen C
- Subjects
- Antiviral Agents therapeutic use, CD8-Positive T-Lymphocytes, Genotype, Hepacivirus genetics, Humans, Programmed Cell Death 1 Receptor genetics, Recurrence, Treatment Outcome, Hepatitis C, Chronic drug therapy
- Abstract
Reducing the treatment duration for chronic hepatitis C could be an important tool in the effort to reach the elimination goals set by the World Health Organization. The current challenge is to predict the target group who will achieve sustained virological response at week 12 (SVR12) with shorter treatment duration. The aim of this exploratory study was to characterize immune subsets with focus on inhibitory receptors in patients who experienced SVR12 or virological relapse following four weeks treatment with glecaprevir/pibrentasvir with or without ribavirin. A total of 32 patients were included in this study of whom 21 achieved SVR12 and 11 had virological relapse. All available samples at baseline (n = 31) and end of treatment (EOT) (n = 30) were processed for flow cytometric analysis in order to measure the expression of PD-1, 2B4, BY55, CTLA-4, TIM-3 and LAG-3 on 12 distinct T cell subsets. At baseline, patients with SVR12 (n=21) had numerically lower frequencies of inhibitory receptors for 83% (60/72) of the investigated T-cell subtypes. The most significant difference observed between the two groups was a lower frequency of stem cell-like memory T-cells CD4
+ PD1+ in the SVR group (p = 0.007). Furthermore, we observed a significant positive correlation between baseline viral load and the expression of PD-1 on the total CD8+ T-cells and effector memory T-cells CD4+ and CD8+ for patients with virological relapse. This study suggests a measurable immunologic phenotype at baseline of patients achieving SVR12 after short treatment compared to patients with virological relapse., Competing Interests: PC and AØ have received research grants from AbbVie, Gilead and MSD, not related to this study and have received travel and conference support from AbbVie, Gilead and MSD. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Madsen, Christensen, Øvrehus, Bryde, Holm, Lillevang and Nielsen.)- Published
- 2022
- Full Text
- View/download PDF
20. Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster Vaccination.
- Author
-
Pedersen RM, Bang LL, Madsen LW, Sydenham TV, Johansen IS, Jensen TG, Justesen US, and Andersen TE
- Subjects
- BNT162 Vaccine, COVID-19 Vaccines, Humans, Vaccination, COVID-19 prevention & control, SARS-CoV-2
- Abstract
The SARS-CoV-2 Omicron variant BA.2 sublineage is rapidly replacing earlier Omicron lineages, suggesting BA.2 has increased vaccine evasion properties. We measured neutralization titers of authentic BA.1 and BA.2 isolates in serum samples from persons who received the BNT162b2 booster vaccine. All samples neutralized BA.1 and BA.2 at equal median values.
- Published
- 2022
- Full Text
- View/download PDF
21. Soluble inflammatory mediators identify HCV patients who may be cured with four weeks of antiviral treatment.
- Author
-
Khera T, Madsen LW, Du Y, Lillevang ST, Christensen PB, and Wedemeyer H
- Subjects
- Antiviral Agents, Genotype, Hepacivirus, Humans, Inflammation Mediators, Proline therapeutic use, Quinoxalines adverse effects, Hepatitis C drug therapy, Hepatitis C, Chronic drug therapy
- Abstract
Soluble inflammatory mediators (SIM) can be predictive of treatment outcome in antiviral treatment of chronic hepatitis C. Recently, it was shown that a subgroup of patients can be cured with four weeks of therapy. We here profiled patients for 70 SIM before and during treatment of hepatitis C with glecaprevir/pibrentasvir (GLE/PIB) +/- ribavirin. Proximity extension assay was performed in a total of 32 patients. Pre-treatment SIM profiles did not distinguish patients achieving an SVR (n = 21) from patients experiencing antiviral relapse (n = 11). However, after 4 weeks of therapy, eight markers were identified that could distinguish patients with SVR from the relapsed group, namely MMP-10, CCL20, CXCL11, FGF-23, TNF, MCP-2, IL-18R1 and CXCL10. Thus, this study shows that a distinct on-treatment immune profile is associated with cure of HCV infection after ultrashort treatment., (© 2022 The Authors. Journal of Viral Hepatitis published by John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
22. Four Weeks Treatment with Glecaprevir/Pibrentasvir + Ribavirin-A Randomized Controlled Clinical Trial.
- Author
-
Madsen LW, Christensen PB, Hansen JF, Røge BT, Holm DK, Dröse S, and Øvrehus A
- Subjects
- Aminoisobutyric Acids, Antiviral Agents therapeutic use, Benzimidazoles, Cyclopropanes, Humans, Lactams, Macrocyclic, Leucine analogs & derivatives, Pandemics, Proline analogs & derivatives, Pyrrolidines, Quinoxalines, Ribavirin therapeutic use, Sulfonamides, COVID-19, Hepatitis C, Chronic drug therapy
- Abstract
Enhancing treatment uptake for hepatitis C to achieve the elimination goals set by the World Health Organization could be achieved by reducing the treatment duration. The aim of this study was to compare the sustained virological response at week 12 (SVR12) after four weeks of glecaprevir/pibrentasvir (GLE/PIB) + ribavirin compared to eight weeks of GLE/PIB and to estimate predictors for SVR12 with four weeks of treatment through a multicenter open label randomized controlled trial. Patients were randomized 2:1 (4 weeks:8 weeks) and stratified by genotype 3 and were treatment naïve of all genotypes and without significant liver fibrosis. A total of 27 patients were analyzed for predictors for SVR12, including 15 from the first pilot phase of the study. In the ‘modified intention to treat’ group, 100% (7/7) achieved cure after eight weeks and for patients treated for four weeks the SVR12 was 58.3% (7/12). However, patients with a baseline viral load <2 mill IU/mL had 93% SVR12. The study closed prematurely due to the low number of included patients due to the COVID-19 pandemic. Our results suggest that viral load should be taken into account when considering trials of short course treatment.
- Published
- 2022
- Full Text
- View/download PDF
23. A multi-level intervention to eliminate hepatitis C from the Region of Southern Denmark: the C-Free-South project.
- Author
-
Dröse S, Øvrehus ALH, Holm DK, Madsen LW, Mössner BK, Søholm J, Hansen JF, Røge BT, and Christensen PB
- Subjects
- Antiviral Agents therapeutic use, Denmark epidemiology, Hepatitis C Antibodies, Humans, Mass Screening, Hepacivirus genetics, Hepatitis C diagnosis, Hepatitis C epidemiology, Hepatitis C prevention & control
- Abstract
Denmark has signed the WHO strategy to eliminate hepatitis C virus (HCV). In the absence of a national strategy for elimination, a local action plan was developed in the Region of Southern Denmark (RSD). The aim of the strategy is to diagnose 90% of HCV-infected persons and treat 80% of those diagnosed by 2025. The strategy was developed by reviewing Danish data on HCV epidemiology and drug use to identify key populations for screening, linkage to care, and treatment. Based on available published data from 2016, an estimated 3028 persons in the RSD were HCV-RNA positive (population prevalence 0.21%). Of these, 1002 were attending clinical care, 1299 were diagnosed but not in clinical care, and 727 were undiagnosed. Three different interventions targeting the HCV-infected population and two interventions for HCV surveillance are planned to achieve elimination. The "C-Free-South" strategy aims to eliminate HCV in our region by identifying (90%) and treating (80%) of infected persons by the end of 2025, 5 years earlier than the WHO elimination target date., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
24. Rectally shed SARS-CoV-2 in COVID-19 inpatients is consistently lower than respiratory shedding and lacks infectivity.
- Author
-
Pedersen RM, Tornby DS, Bang LL, Madsen LW, Skov MN, Sydenham TV, Steinke K, Jensen TG, Johansen IS, and Andersen TE
- Subjects
- Cohort Studies, Humans, Inpatients, Pharynx, RNA, Viral genetics, Virus Shedding, COVID-19, SARS-CoV-2
- Abstract
Objectives: Assessment of whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been propagated during intestinal passage and infectivity is conserved when shed rectally by hospitalized individuals., Methods: An exploratory cohort study including 28 inpatients with coronavirus disease 2019 with estimation of RNA levels by RT-PCR and of viral infectivity by culturing of viral material sampled concomitantly and identically from pharynx and rectum., Results: SARS-CoV-2 RNA was detected more frequently (91%, 30/33 versus 42%, 14/33, p <0.0001) and at higher concentrations (median levels 2 190 186 IU/mL versus 13 014 IU/mL, p <0.0001) in the pharyngeal swabs than in the rectal swabs. For all sample pairs (n = 33) the rectal swabs contained undetectable or lower SARS-CoV-2 RNA concentrations than their paired pharyngeal swabs. Replicative virus was found in 37% (11/30) of the PCR-positive pharyngeal swabs, whereas none of the PCR-positive rectal swabs could be cultured (0%, 0/14) despite containing SARS-CoV-2 RNA concentrations up to 1 544 691 IU/mL., Conclusions: Our data draw into question whether SARS-CoV-2 is transmitted readily from faeces., (Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
25. Inferior cure rate in pilot study of 4-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C.
- Author
-
Madsen LW, Christensen PB, Fahnøe U, Pedersen MS, Bukh J, and Øvrehus A
- Subjects
- Aminoisobutyric Acids, Antiviral Agents therapeutic use, Benzimidazoles, Cyclopropanes, Genotype, Hepacivirus genetics, Humans, Lactams, Macrocyclic, Leucine analogs & derivatives, Pilot Projects, Proline analogs & derivatives, Pyrrolidines, Quinoxalines therapeutic use, Sulfonamides, Sustained Virologic Response, Hepatitis C, Chronic drug therapy, Ribavirin therapeutic use
- Abstract
Background & Aims: Shortening the treatment duration for chronic hepatitis C may increase feasibility and reduce the cost of cure. The aims of this study were to compare 4 weeks of glecaprevir/pibrentasvir (GLE/PIB) treatment with and without ribavirin for patients with chronic hepatitis C and favourable baseline characteristics and to monitor the development of resistance-associated substitutions (RAS) and re-treatment outcomes if treatment failed., Methods: We performed an open-label single-centre randomized controlled trial, in which patients with chronic hepatitis C were randomized 1:1 to GLE/PIB ± ribavirin, stratified by genotype 3. The main inclusion criteria were treatment-naive patients, aged 18-49 with all genotypes accepted, and absence of liver fibrosis, determined by liver stiffness measurement less than 8 kPa. Viral genome sequences were determined by deep sequencing at baseline and at the time of relapse., Results: A total of 32 patients started treatment. Sustained virological response at week 12 (SVR12) was 59% (10/17) for GLE/PIB without ribavirin and 73% (11/15) for GLE/PIB with ribavirin. Drug target-specific NS5A RAS were detected at baseline for 45% (5/11) of patients with treatment failure and for 14% (3/21) of patients who achieved SVR12. Ten failure patients were retreated 12 weeks with sofosbuvir-based regimens; all have been cured., Conclusions: In this pilot study of 4-week treatment with GLE/PIB with and without ribavirin, we found that baseline RAS were more frequent in patients with virological failure. Development of RAS did occur after short treatment but did not result in retreatment failure with a different regimen. EudraCT no: 2017-005179-21., (© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
26. Characterization of a Novel Hepatitis C Virus Genotype 1 Subtype from a Patient Failing 4 Weeks of Glecaprevir-Pibrentasvir Treatment.
- Author
-
Pedersen MS, Fahnøe U, Madsen LW, Christensen PB, Øvrehus A, and Bukh J
- Abstract
Limited information is available in relation to surveillance, genotyping, genome sequences, and treatment outcomes for rare hepatitis C virus variants. Here, we have characterized a novel subtype of major hepatitis C virus genotype 1, which was deep sequenced before and after treatment failure with 4 weeks of glecaprevir and pibrentasvir.
- Published
- 2021
- Full Text
- View/download PDF
27. SARS-CoV-2 viral load as a predictor for disease severity in outpatients and hospitalised patients with COVID-19: A prospective cohort study.
- Author
-
Knudtzen FC, Jensen TG, Lindvig SO, Rasmussen LD, Madsen LW, Hoegh SV, Bek-Thomsen M, Laursen CB, Nielsen SL, and Johansen IS
- Subjects
- Adult, Aged, Female, Hospitalization, Humans, Male, Middle Aged, Outpatients, Prospective Studies, SARS-CoV-2 isolation & purification, COVID-19 epidemiology, COVID-19 virology, Severity of Illness Index, Viral Load
- Abstract
Introduction: We aimed to examine if severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR) cycle quantification (Cq) value, as a surrogate for SARS-CoV-2 viral load, could predict hospitalisation and disease severity in adult patients with coronavirus disease 2019 (COVID-19)., Methods: We performed a prospective cohort study of adult patients with PCR positive SARS-CoV-2 airway samples including all out-patients registered at the Department of Infectious Diseases, Odense University Hospital (OUH) March 9-March 17 2020, and all hospitalised patients at OUH March 10-April 21 2020. To identify associations between Cq-values and a) hospital admission and b) a severe outcome, logistic regression analyses were used to compute odds ratios (OR) and 95% Confidence Intervals (CI), adjusting for confounding factors (aOR)., Results: We included 87 non-hospitalised and 82 hospitalised patients. The median baseline Cq-value was 25.5 (interquartile range 22.3-29.0). We found a significant association between increasing Cq-value and hospital-admission in univariate analysis (OR 1.11, 95% CI 1.04-1.19). However, this was due to an association between time from symptom onset to testing and Cq-values, and no association was found in the adjusted analysis (aOR 1.08, 95% CI 0.94-1.23). In hospitalised patients, a significant association between lower Cq-values and higher risk of severe disease was found (aOR 0.89, 95% CI 0.81-0.98), independent of timing of testing., Conclusions: SARS-CoV-2 PCR Cq-values in outpatients correlated with time after symptom onset, but was not a predictor of hospitalisation. However, in hospitalised patients lower Cq-values were associated with higher risk of severe disease., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2021
- Full Text
- View/download PDF
28. Rectally shed SARS-CoV-2 lacks infectivity: time to rethink faecal-oral transmission?
- Author
-
Pedersen RM, Tornby DS, Bang LL, Madsen LW, Skov MN, Jensen TG, Johansen IS, and Andersen TE
- Subjects
- Feces, Humans, COVID-19, SARS-CoV-2
- Published
- 2021
- Full Text
- View/download PDF
29. Prolonged viral shedding of SARS-CoV-2 in two immunocompromised patients, a case report.
- Author
-
Niyonkuru M, Pedersen RM, Assing K, Andersen TE, Skov MN, Johansen IS, and Madsen LW
- Subjects
- Antibodies, Viral, Humans, Immunocompromised Host, Virus Shedding, COVID-19, SARS-CoV-2
- Abstract
Background: The duration of viable Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) shedding in immunocompromised patients is still unknown. This case report describes the duration of viable SARS-CoV-2 in two immunocompromised patients with completely different clinical courses and further addresses the immunological aspects., Case Presentations: Oropharyngeal swaps were collected continuously during hospitalization for two immunocompromised patients infected with SARS-CoV-2 and sent for analysis to real time reverse transcription polymerase chain reaction (RT-PCR), viral culture assessed by plaque assay and full genome sequencing. Blood samples for flow cytometry and further immunological analysis were taken once during admission. One patient was without symptoms of Coronavirus disease 2019 (COVID-19) whereas the other had severe respiratory symptoms requiring a stay at an intensive care unit (ICU) and treatment with remdesivir and dexamethasone. Despite their difference in clinical courses, they both continuously shed SARS-CoV-2 with high viral loads in culture. Both patients had undetectable anti SARS-CoV-2 IgG levels about 2 weeks after the first positive real time RT-PCR test of SARS-CoV-2, marked expansions of virus reactive CD8+ T cells but cellular markers indicative of attenuated humoral immunity., Conclusions: Our case illustrates the importance of distinguishing isolation guidelines for patients infected with SARS-CoV-2 according to their immunological status. Furthermore, it demonstrates the need for immune markers relating to viral shedding in immunocompromised patients., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
30. Low mortality of hospitalised patients with COVID-19 in a tertiary Danish hospital setting.
- Author
-
Madsen LW, Lindvig SO, Rasmussen LD, Knudtzen FC, Laursen CB, Øvrehus A, Nielsen SL, and Johansen IS
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Denmark epidemiology, Female, Hospital Mortality, Hospitalization, Humans, Intensive Care Units, Male, Middle Aged, Prospective Studies, Tertiary Care Centers, Young Adult, COVID-19 mortality, SARS-CoV-2
- Abstract
Objectives: We aimed to describe clinical characteristics and outcomes of admitted COVID-19 patients in a Danish hospital setting where an early active government intervention was taken., Methods: Prospective cohort study including all admitted patients to the COVID-19 unit at Odense University Hospital from March 10 to April 21, 2020. Patients were assessed by a multidisciplinary team at admission. Outcome parameters were development of acute respiratory distress syndrome (ARDS), intensive care unit (ICU) admission, death and admission time., Results: We included 83 patients (median age 62 years, 62.7% male). At hospitalization, 31.3% needed oxygen supplementation and the median National Early Warning Score was four. Median admission time was 7 days (Interquartile ranges (IQR) 3-12). In total, ARDS was diagnosed in 33.7% (28/83) of the patients corresponding to an incidence rate of 7.1 per 100 person days (95% CI: 4.1-10.2). Overall 13 patients (15.7%) were transferred to the ICU of whom 11 (84.6%) received corticosteroids.. No patients died while admitted to the ICU. Four patients (4.8%) died during admission., Conclusion: Despite similar patient characteristics compared to those reported by others, we found a low overall mortality of < 5%., (Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
31. Incidence, prevalence and risk factors for hepatitis C in Danish prisons.
- Author
-
Søholm J, Holm DK, Mössner B, Madsen LW, Hansen JF, Weis N, Sauer AP, Awad T, and Christensen PB
- Subjects
- Adult, Denmark epidemiology, Dried Blood Spot Testing methods, Female, Hepatitis C diagnosis, Hepatitis C etiology, Humans, Incidence, Male, Middle Aged, Prevalence, RNA, Viral genetics, Risk Assessment, Seroepidemiologic Studies, Substance Abuse, Intravenous complications, Hepacivirus genetics, Hepatitis C epidemiology, Prisoners statistics & numerical data, Substance Abuse, Intravenous epidemiology
- Abstract
Hepatitis C virus (HCV) infection is prevalent among people in prison and prisons could therefore represent a unique opportunity to test risk groups for HCV. The aim of this sero-epidemiological study was to determine the incidence and prevalence of HCV infection and the corresponding risk factors in Danish prisons. Participants, recruited from eight Danish prisons, were tested for HCV using dried blood spots and filled out a questionaire with demographic data and risk factors for HCV infection. In total, 76.9% (801/1041) of all eligible prisoners consented to participate. The prevalence of HCV RNA positive prisoners was 4.2% (34/801) and the in-prison incidence rate was 0.7-1.0 per 100PY overall and 18-24/100PY among PWIDs. Infected prisoners were older than the overall population with a mean age of 42 years and only 17.6% (6/34) were younger than 35 years. The prevalence of PWID was 8.5% (68/801) and only 3% (2/68) of PWID were younger than 25 years. Among the PWID, 85.3% (58/68) had ever received opioid substitution therapy (OST) and 47.1% (32/68) were currently receiving OST. Risk factors associated with HCV infection were intravenous drug use, age ≥ 40 years, and being incarcerated ≥ 10 years. In conclusion, the prevalence of PWID in Danish prisons is low, possibly reflecting a decrease in injecting among the younger generation. This together with OST coverage could explain the low prevalence of HCV infection. However among PWIDs in prison the incidence remains high, suggesting a need for improved HCV prevention in prison., Competing Interests: TA is an employee of AbbVie, but doesn’t owe AbbVie stock or stock options. NW has been clinical investigator, lecturer and advisory board member for BMS, MSD and AbbVie; lecturer and/or advisory board member for Gilead and GSK. Honorarium paid to her institution. APS has received payment for serving as an advisory board member for AbbVie. The authors confirm that no other known conflicts of interest associated with this publication apart from those disclosed. This does not alter our adherence to PLOS ONE’s policies on sharing data and materials.
- Published
- 2019
- Full Text
- View/download PDF
32. Depressive symptoms are frequent among drug users, but not associated with hepatitis C infection.
- Author
-
Madsen LW, Fabricius T, Hjerrild S, Hansen TM, Mössner BK, Birkemose I, Skamling M, and Christensen PB
- Subjects
- Adult, Cross-Sectional Studies, Denmark epidemiology, Female, Hepatitis C Antibodies blood, Humans, Male, Middle Aged, Prevalence, RNA, Viral blood, Depression epidemiology, Depression pathology, Drug Users, Hepatitis C complications, Substance-Related Disorders complications
- Abstract
Aim: To compare the prevalence and severity of depressive symptoms among drug users with and without hepatitis C virus (HCV) infection., Methods: This was a cross-sectional survey study carried out at the 2 major drug treatment centres on the island of Funen, Denmark. Participants were drug users presenting to the 2 treatment centres. Individuals with chronic hepatitis B virus or HIV infection were excluded. Participants completed the Major Depression Inventory (MDI) questionnaire when presenting at the centres. Patients with MDI scores indicating severe depression (total MDI score ≥ 35) were referred for treatment evaluation. Hepatitis C status was classified by the presence of anti-HCV as a marker of HCV exposure and HCV-RNA as a marker of ongoing infection., Results: Two hundred and sixty-eight patients were included, of whom 235 (88%) had complete serological testing; 100 (43%, 95% confidence interval (CI) 36-49%) had chronic hepatitis C. The median MDI score was 22 (interquartile range 12-33); 32% (95% CI 26-39%) had a score compatible with depression and 14% (95% CI 10-19%) were rated as severe depression. Depression was not associated with hepatitis C (HCV-infected 29%, non-infected 35%; p = 0.25). Forty-one percent (11/27) of the evaluated participants started antidepressant treatment., Conclusions: Our study demonstrated a high prevalence of depressive symptoms among drug users, but this was not more frequent among HCV-infected patients. The high overall prevalence of depression underlines the relevance of screening for depression in patients who are drug users.
- Published
- 2014
- Full Text
- View/download PDF
33. GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation.
- Author
-
Madsen LW, Knauf JA, Gotfredsen C, Pilling A, Sjögren I, Andersen S, Andersen L, de Boer AS, Manova K, Barlas A, Vundavalli S, Nyborg NC, Knudsen LB, Moelck AM, and Fagin JA
- Subjects
- Animals, Calcitonin blood, Calcitonin metabolism, Female, Glucagon-Like Peptide 1 analogs & derivatives, Glucagon-Like Peptide 1 pharmacology, Glucagon-Like Peptide-1 Receptor, Immunohistochemistry methods, Ligands, Liraglutide, Male, Mice, Mice, Knockout, Models, Genetic, Phosphoproteins chemistry, Proto-Oncogene Proteins c-ret genetics, Signal Transduction, TOR Serine-Threonine Kinases metabolism, Time Factors, Receptors, Glucagon agonists, Thyroid Gland metabolism
- Abstract
Liraglutide and exenatide are glucagon-like peptide receptor (GLP-1R) agonists used in the treatment of type 2 diabetes. Both molecules have been associated with the development of thyroid C-cell tumors after lifetime exposure in rodents. Previously, it has been reported that these tumors are preceded by increased plasma calcitonin and C-cell hyperplasia. We can now document that the murine C-cell effects are mediated via GLP-1R. Thus, 13 wk of continuous exposure to GLP-1R agonists was associated with marked increases in plasma calcitonin and in the incidence of C-cell hyperplasia in wild-type mice. In contrast, similar effects were not seen in GLP-1R knockout mice. Human C-cell cancer is often caused by activating mutations in the rearranged-during-transfection (RET) protooncogene. We developed an immunohistochemical method to assess RET activation in tissues. Liraglutide dosing to mice was not found to activate RET. Further evaluation of the signaling pathways demonstrated that liraglutide increased ribosomal S6, but not MAPK kinase, phosphorylation. These observations are consistent with effects of GLP-1R agonists on rodent C cells being mediated via mammalian target of rapamycin activation in a RET- and MAPK-independent manner.
- Published
- 2012
- Full Text
- View/download PDF
34. [Peritoneal tuberculosis in a patient with suspected disseminated ovarian cancer].
- Author
-
Madsen LW, Neumann G, and Pedersen C
- Subjects
- Adult, Diagnosis, Differential, Female, Humans, Multimodal Imaging, Ovarian Neoplasms diagnosis, Peritonitis, Tuberculous diagnostic imaging, Peritonitis, Tuberculous pathology, Positron-Emission Tomography, Tomography, X-Ray Computed, Peritonitis, Tuberculous diagnosis
- Abstract
We present a case study of a 43 year-old female immigrant from Turkey with abdominal pain, ascites and elevated cancer antigen 125. The symptoms were similar to those of ovarian cancer, and imaging (computed tomography (CT), positron emission tomography/computed tomography and magnetic resonance imaging) supported this suspicion. Peritoneal biopsy from laparoscopy showed granulomas with central necrosis. Microscopy, culture and polymerase chain reaction from biopsy samples were negative for Mycobacterium tuberculosis. Follow-up with a CT scan after six months of full tuberculosis treatment showed normal conditions. Peritoneal tuberculosis is a diagnostic challenge, but should be considered in case of immigrants from high-risk areas.
- Published
- 2012
35. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.
- Author
-
Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, Gotfredsen C, Egerod FL, Hegelund AC, Jacobsen H, Jacobsen SD, Moses AC, Mølck AM, Nielsen HS, Nowak J, Solberg H, Thi TD, Zdravkovic M, and Moerch U
- Subjects
- Animals, Blotting, Western, Calcitonin genetics, Cell Line, Cells, Cultured, Cyclic AMP metabolism, Diabetes Mellitus, Type 1 genetics, Diabetes Mellitus, Type 1 metabolism, Dose-Response Relationship, Drug, Enzyme-Linked Immunosorbent Assay, Gene Expression drug effects, Glucagon-Like Peptide 1 pharmacology, Glucagon-Like Peptide-1 Receptor, Humans, Immunohistochemistry, In Situ Hybridization, Liraglutide, Macaca fascicularis, Mice, Mice, Knockout, Obesity genetics, Obesity metabolism, RNA, Messenger genetics, RNA, Messenger metabolism, Radioimmunoassay, Rats, Rats, Sprague-Dawley, Receptors, Glucagon genetics, Reverse Transcriptase Polymerase Chain Reaction, Species Specificity, Thyroid Gland cytology, Thyroid Gland metabolism, Calcitonin metabolism, Cell Proliferation drug effects, Glucagon-Like Peptide 1 analogs & derivatives, Receptors, Glucagon metabolism, Thyroid Gland drug effects
- Abstract
Liraglutide is a glucagon-like peptide-1 (GLP-1) analog developed for type 2 diabetes. Long-term liraglutide exposure in rodents was associated with thyroid C-cell hyperplasia and tumors. Here, we report data supporting a GLP-1 receptor-mediated mechanism for these changes in rodents. The GLP-1 receptor was localized to rodent C-cells. GLP-1 receptor agonists stimulated calcitonin release, up-regulation of calcitonin gene expression, and subsequently C-cell hyperplasia in rats and, to a lesser extent, in mice. In contrast, humans and/or cynomolgus monkeys had low GLP-1 receptor expression in thyroid C-cells, and GLP-1 receptor agonists did not activate adenylate cyclase or generate calcitonin release in primates. Moreover, 20 months of liraglutide treatment (at >60 times human exposure levels) did not lead to C-cell hyperplasia in monkeys. Mean calcitonin levels in patients exposed to liraglutide for 2 yr remained at the lower end of the normal range, and there was no difference in the proportion of patients with calcitonin levels increasing above the clinically relevant cutoff level of 20 pg/ml. Our findings delineate important species-specific differences in GLP-1 receptor expression and action in the thyroid. Nevertheless, the long-term consequences of sustained GLP-1 receptor activation in the human thyroid remain unknown and merit further investigation.
- Published
- 2010
- Full Text
- View/download PDF
36. Growth differences of male and female Göttingen minipigs during ad libitum feeding: a pilot study.
- Author
-
Bollen PJ, Madsen LW, Meyer O, and Ritskes-Hoitinga J
- Subjects
- Aging, Animal Nutritional Physiological Phenomena, Animals, Dietary Fats administration & dosage, Dietary Proteins administration & dosage, Energy Intake, Female, Male, Pilot Projects, Weight Gain, Diet, Sex Characteristics, Swine growth & development, Swine, Miniature growth & development
- Abstract
Even though minipigs have been used in biomedical research for nearly half a century now, no specific nutrient requirements are available. For that reason a series of studies into the nutrient requirements of Göttingen minipigs were carried out. Firstly, a pilot study was carried out to determine the ad libitum feed intake (FI) during growth, as a reference for later feed restriction studies. Four male and four female minipigs were fed two types of diet, one standard pig diet (20.6% crude protein; 11.7% crude fat; 13.5 mJ/kg DM metabolizable energy) and one diet specially designed for minipigs (12.0% crude protein; 2.9% crude fat; 11.9 MJ/kg DM metabolizable energy). When fed ad libitum for 13 weeks, female Göttingen minipigs developed a significantly (P<0.05) higher body weight (BW) than males (27.4 vs 16.6 kg) on either diet. The large difference in growth between male and female Göttingen minipigs did not appear to be the result from differences in metabolizable energy intake. Metabolizable energy intake of male and female Göttingen minipigs could be predicted by ME=1877 kJxBW(0.61). Both male and female Göttingen minipigs became obese when fed ad libitum, defined by relative backfat thickness. Relative backfat thickness ranged from 5 to 13 cm/100 kg. Females had thicker relative backfat layers than males. Remarkably, no large changes in haematology and clinical chemistry occurred in ad libitum fed Göttingen minipigs as compared to reference values, and no abnormalities other than enlarged fat reserves were observed at necropsy. Apparently, Göttingen minipigs do not restrain FI voluntarily, and restricted feeding is therefore indicated to prevent obesity.
- Published
- 2005
- Full Text
- View/download PDF
37. Immune complex-associated thrombocytopenic purpura syndrome in sexually mature Göttingen minipigs.
- Author
-
Carrasco L, Madsen LW, Salguero FJ, Núñez A, Sánchez-Cordón P, and Bollen P
- Subjects
- Anemia etiology, Anemia pathology, Anemia veterinary, Animals, Cell Count veterinary, Complement C1q analysis, Female, Glomerulonephritis, Membranoproliferative complications, Glomerulonephritis, Membranoproliferative pathology, Glomerulonephritis, Membranoproliferative veterinary, Hemorrhage etiology, Hemorrhage pathology, Hemorrhage veterinary, Immune Complex Diseases complications, Immune Complex Diseases pathology, Immunoenzyme Techniques veterinary, Immunoglobulins analysis, Kidney Glomerulus chemistry, Kidney Glomerulus immunology, Kidney Glomerulus pathology, Male, Megakaryocytes pathology, Purpura, Thrombocytopenic complications, Purpura, Thrombocytopenic pathology, Sexual Maturation, Swine, Swine Diseases immunology, Syndrome, Antigen-Antibody Complex immunology, Immune Complex Diseases veterinary, Purpura, Thrombocytopenic veterinary, Swine Diseases pathology, Swine, Miniature immunology
- Abstract
Eleven cases of thrombocytopenic purpura (TP) in sexually mature male or female Göttingen minipigs occurred sporadically over 3 1/2 years in a closed breeding colony protected by strict barrier conditions. Typical clinical signs of TP, including extensive subcutaneous haemorrhages, were seen in all affected animals. Haematological abnormalities included marked thrombocytopenia and anaemia. A consistent histopathological finding was the presence of membranoproliferative lesions in the renal glomeruli. Immunohistochemically, glomerular deposits were positively labelled for complement factor C1q and often also for immunoglobulins. Bone marrow findings consisting of increased numbers of immature and apoptotic megakaryocytes were compatible with a state of increased platelet consumption. Based on the combined presence of thrombocytopenia and renal immune complexes, it is suggested that the syndrome was related to a type III hypersensitivity reaction. However, further studies are needed to verify this hypothesis., (Copyright 2002 Elsevier Science Ltd.)
- Published
- 2003
- Full Text
- View/download PDF
38. Bacterial colonization and invasion in pigs experimentally exposed to Streptococcus suis serotype 2 in aerosol.
- Author
-
Madsen LW, Bak H, Nielsen B, Jensen HE, Aalbaek B, and Riising HJ
- Subjects
- Aerosols, Animals, Immunohistochemistry veterinary, Male, Palatine Tonsil immunology, Palatine Tonsil microbiology, Streptococcal Infections microbiology, Streptococcal Infections pathology, Swine, Swine Diseases pathology, Streptococcal Infections veterinary, Streptococcus suis pathogenicity, Swine Diseases microbiology
- Abstract
A recently developed porcine model for aerogenous infection with Streptococcus suis serotype 2 was applied in a study of the phases of bacterial colonization and initial invasion. Eighteen pigs were exposed to aerosolized S. suis serotype 2 after pre-exposure to mild acetic acid in aerosol. The animals were killed consecutively within the first six days after challenge. After death, all animals were necropsied and examined by bacteriology, histopathology, and immunohistochemistry. Systemic infection was established in four out of 18 animals exposed to S. suis serotype 2. All systemically infected animals developed clinical signs and lesions typical of the infection. In four additional animals, subclinical infection was demonstrated by re-isolation of S. suis from the palatine tonsil. However, in all 18 challenged animals, immunohistochemistry demonstrated S. suis serotype 2 antigen in the palatine and/or nasopharyngeal tonsils. In all four systemically infected animals, S. suis serotype 2 antigen was also found in the mandibular lymph node. These observations point towards the tonsils as possible portals of entry for S. suis serotype 2 with subsequent lymphogenous spread. Thus, the present findings parallel the proposed pathogenesis for S. suis serotype 1 infection in pigs.
- Published
- 2002
- Full Text
- View/download PDF
39. Streptococcus suis serotype 2 infection in pigs: new diagnostic and pathogenetic aspects.
- Author
-
Madsen LW, Svensmark B, Elvestad K, Aalbaek B, and Jensen HE
- Subjects
- Animals, Antigens, Bacterial analysis, Bacteriological Techniques veterinary, Brain immunology, Brain pathology, Immunohistochemistry veterinary, Palatine Tonsil microbiology, Palatine Tonsil pathology, Streptococcal Infections microbiology, Streptococcal Infections pathology, Streptococcus suis classification, Streptococcus suis isolation & purification, Swine, Swine Diseases pathology, Streptococcal Infections veterinary, Streptococcus suis physiology, Swine Diseases microbiology
- Abstract
In a study aimed at improving the diagnosis and elucidating the pathogenesis of Streptococcus suis serotype 2 infection in pigs, a combination of bacterial culture and histopathological and immunohistochemical examination was applied to a range of tissues from 42 naturally infected pigs with typical macroscopical lesions. By culture, 21 pigs (50%) were shown to be systemically infected with S. suis serotype 2; seven (17%) were infected with S. suis serotype 7, two with other bacteria, and 12 yielded no bacterial pathogens. The highest isolation rate for S. suis serotype 2 was obtained from the lateral cerebral ventricles and other regions of the brain, whereas the bacterium was only rarely isolated from the liver or spleen. Immunohistochemically, a diagnosis of S. suis serotype 2 infection was obtained in two of 12 (17%) animals from which no pathogens had been cultured. Moreover, immunohistochemistry differed from culture in revealing a greater number of positive tissue specimens. The microanatomical distribution of bacteria pointed toward the pharyngeal and palatine tonsils as principal portals of entry. Furthermore, S. suis serotype 2 bacteria were frequently identified immunohistochemically in the regional lymph nodes of the upper respiratory tract, possibly reflecting primary lymphogenous spread from the tonsils.
- Published
- 2002
- Full Text
- View/download PDF
40. Actinobacillus pleuropneumoniae demonstrated in situ in exudative meningitis and nephritis.
- Author
-
Madsen LW, Boye M, Jensen TK, and Svensmark B
- Subjects
- Actinobacillus Infections complications, Actinobacillus Infections diagnosis, Actinobacillus pleuropneumoniae genetics, Animals, In Situ Hybridization, Fluorescence veterinary, Male, Meningitis, Bacterial complications, Meningitis, Bacterial diagnosis, Nephritis complications, Nephritis diagnosis, RNA, Ribosomal, 16S isolation & purification, Swine, Swine Diseases microbiology, Actinobacillus Infections veterinary, Actinobacillus pleuropneumoniae isolation & purification, Meningitis, Bacterial veterinary, Nephritis veterinary, Swine Diseases diagnosis
- Published
- 2001
41. An enzyme-based in situ hybridisation method for the identification of Streptococcus suis.
- Author
-
Madsen LW, Boye M, and Jensen HE
- Subjects
- Animals, Endopeptidase K, Formaldehyde, In Situ Hybridization methods, Organ Specificity, RNA, Bacterial analysis, RNA, Ribosomal, 16S analysis, Ribotyping methods, Streptococcus classification, Swine, Tissue Embedding, Streptococcus isolation & purification
- Abstract
A method for enzyme-based in situ hybridisation of Streptococcus suis was developed. It enables the light microscopic localization of bacterial ribosomal RNA (rRNA) in formalin-fixed paraffin-embedded tissues. A unique sequence in the 16S rRNA of S. suis was targeted. Different pretreatment protocols were applied to facilitate probe penetration and multiple detection systems were tested. The results were compared to those obtained by immunohistochemistry. Pretreatment was necessary to obtain a signal by in situ hybridisation. The use of proteinase-K pretreatment was optimal regarding sensitivity and preservation of tissue morphology. A strong specific in situ hybridisation signal was achieved in tissue sections containing S. suis in microcolonies and the microanatomy of the surrounding tissue was easily assessed. However, the signal distribution differed from that found immunohistochemically and low-grade infection could not be detected by in situ hybridisation. These findings were interpreted as reflecting the physiological state of the bacteria. Thus, this method could prove useful in future studies of the infection pathogenesis.
- Published
- 2001
- Full Text
- View/download PDF
42. Aerogenous infection of microbiologically defined minipigs with Streptococcus suis serotype 2. A new model.
- Author
-
Madsen LW, Aalbaek B, Nielsen OL, and Jensen HE
- Subjects
- Animals, Antigens, Bacterial metabolism, Bacteremia microbiology, Bacteremia pathology, Disease Models, Animal, Female, Humans, Immunohistochemistry, Immunosuppressive Agents administration & dosage, Male, Prednisone administration & dosage, Serotyping, Streptococcal Infections microbiology, Streptococcal Infections pathology, Streptococcus suis classification, Streptococcus suis immunology, Swine, Swine, Miniature microbiology, Bacteremia etiology, Streptococcal Infections etiology, Streptococcus suis pathogenicity
- Abstract
Streptococcus suis serotype 2 is the cause of serious infections in animals and humans, but certain aspects of the infection pathogenesis still remain unclear. In this study an experimental model of aerogenous infection and induction of septicemia with S. suis serotype 2 was established in microbiologically defined Göttingen minipigs. Ten animals were exposed to aerosolized S. suis after previous exposure to mild acetic acid in aerosol. Six of the animals were immunosuppressed with prednisolone acetate on different days. All the animals were monitored clinically until euthanasia on days 6 to 13 after exposure. Necropsy was performed and samples were taken for microbiology, histopathology, and immunohistochemistry Three out of four animals immunosuppressed on days 5 to 7 after exposure developed S. suis septicemia, and S. suis could be detected in the tonsil of the soft palate and/or the nasal cavity of all exposed animals. Thus, using the presented model, local as well as systemic infection with S. suis serotype 2 was established in the Göttingen minipig. Since this breed is defined as free of S. suis and a range of other endemic porcine pathogens, the experimental model could prove useful in the study of this infection.
- Published
- 2001
- Full Text
- View/download PDF
43. Otitis interna is a frequent sequela to Streptococcus suis meningitis in pigs.
- Author
-
Madsen LW, Svensmark B, Elvestad K, and Jensen HE
- Subjects
- Animals, Antigens, Bacterial analysis, Cochlea microbiology, Cochlea pathology, Female, Immunohistochemistry veterinary, Labyrinthitis complications, Labyrinthitis microbiology, Labyrinthitis pathology, Male, Meningitis, Bacterial complications, Meningitis, Bacterial microbiology, Meningitis, Bacterial pathology, Retrospective Studies, Streptococcal Infections complications, Streptococcal Infections pathology, Swine, Swine Diseases microbiology, Telencephalon microbiology, Telencephalon pathology, Vestibulocochlear Nerve microbiology, Vestibulocochlear Nerve pathology, Labyrinthitis veterinary, Meningitis, Bacterial veterinary, Streptococcal Infections veterinary, Streptococcus suis growth & development, Swine Diseases pathology
- Abstract
Twenty-eight histologically confirmed cases of porcine leptomeningitis were examined retrospectively, with focus on the pathology of the inner and middle ear, brain, and vestibulocochlear nerve. Tissues were evaluated by histology and immunohistochemistry for Streptococcus suis serotype 2 antigen, and the bacteriologic results were recorded. Exudative otitis interna was diagnosed in 20/28 pigs (71%). The lesions primarily affected the perilymphatic ducts, with consistent involvement of the scala tympani. Perineuritis of the vestibulocochlear nerve was seen in all but four of the ears affected with otitis interna. Immunohistochemically, S. suis serotype 2 antigen was demonstrated in the leptomeningeal, perineural, and labyrinthine exudates in 11 cases. Otitis media was diagnosed in 10/28 pigs (34%), but evidence of extension to the inner ear was not observed. The findings were highly similar to descriptions of meningogenic labyrinthitis in humans and in laboratory animal models. Otitis interna in pigs can also develop via the meningogenic route and is not always, as generally stated, tympanogenic.
- Published
- 2001
- Full Text
- View/download PDF
44. Experimental infection of conventional pigs with Streptococcus suis serotype 2 by aerosolic exposure.
- Author
-
Madsen LW, Nielsen B, Aalbaek B, Jensen HE, Nielsen JP, and Riising HJ
- Subjects
- Aerosols, Animals, Female, Serotyping, Streptococcal Infections etiology, Streptococcus suis classification, Swine, Streptococcal Infections pathology, Streptococcus suis pathogenicity
- Published
- 2001
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.